Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan

Chia-Wen Li, Chia Jui Yang, Hsin Yun Sun, Mao Song Tsai, Shih Ping Lin, Te Yu Lin, Chien Yu Cheng, Yi Chien Lee, Yu Shan Huang, Chun Eng Liu, Yuan Ti Lee, Hung Jen Tang, Ning Chi Wang, Shu Hsing Cheng, Wen-Chien Ko, Chien Ching Hung

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective The study aimed to describe the evolution of the seroprevalence of hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-positive patients included in two cohorts in Taiwan. Methods We retrospectively collected the information on demographic and clinical characteristics of 4,025 and 3,856 HIV-positive Taiwanese, who were aged 18 years or older at designated hospitals around Taiwan in 2004±2007, when an outbreak of HIV infection was occurring, and 2012±2016, when the outbreak was controlled with the implementation of harm reduction program, respectively. Comparisons of HCV seropositivity were made among different age and risk groups for HIV transmission between these two cohorts. Results The overall HCV seroprevalence of the 2004±2007 cohort and 2012±2016 cohort was 43.4% (1,288/2,974) and 18.6% (707/3,793), respectively (P<0.001). The HCV seroprevalence among injecting drug users (IDUs), though decreasing, was constantly high across the two cohorts, 96.4% and 94.0% (P = 0.02), respectively, and all age groups. In contrast, the corresponding figures among men who have sex with men (MSM) and heterosexuals in the two cohorts were 5.9% vs. 3.5% (P = 0.002) and 9.4% vs. 10.9% (P = 0.59), respectively. Among sexually transmitted HIV-positive patients, HCV seropositivity was significantly correlated with age (adjusted odds ratio [aOR], per 1-year increase, 1.03; 95% confidence interval [CI], 1.02±1.05) and a rapid plasma reagin (RPR) titer ≥1:8 (aOR, 1.58; 95% CI, 1.03±2.43) in a multivariate analysis including age, gender, route for HIV transmission, baseline CD4 count and plasma HIV RNA load, the presence of hepatitis B surface antigen, and an RPR titer ≥1:8. Compared with heterosexuals, the aOR for HCV seropositivity among MSM was 0.47 (95% CI, 0.31±0.72). Conclusions HCV seroprevalence among HIV-positive patients in Taiwan decreased with time, probably related to the inclusion of younger adults and more non-IDUs, and remained high among IDUs. HCV seropositivity was associated with age and an RPR titer ≥1:8 among patients who acquired HIV through sexual contact.

Original languageEnglish
Article numbere0194149
JournalPloS one
Volume13
Issue number3
DOIs
Publication statusPublished - 2018 Mar 1

Fingerprint

Hepatitis C virus
Human immunodeficiency virus
Seroepidemiologic Studies
HIV infections
Virus Diseases
Taiwan
Viruses
Hepacivirus
seroprevalence
HIV
Reagins
odds ratio
Drug Users
confidence interval
virus transmission
Odds Ratio
Heterosexuality
drugs
Confidence Intervals
Disease Outbreaks

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Li, C-W., Yang, C. J., Sun, H. Y., Tsai, M. S., Lin, S. P., Lin, T. Y., ... Hung, C. C. (2018). Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan. PloS one, 13(3), [e0194149]. https://doi.org/10.1371/journal.pone.0194149
Li, Chia-Wen ; Yang, Chia Jui ; Sun, Hsin Yun ; Tsai, Mao Song ; Lin, Shih Ping ; Lin, Te Yu ; Cheng, Chien Yu ; Lee, Yi Chien ; Huang, Yu Shan ; Liu, Chun Eng ; Lee, Yuan Ti ; Tang, Hung Jen ; Wang, Ning Chi ; Cheng, Shu Hsing ; Ko, Wen-Chien ; Hung, Chien Ching. / Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan. In: PloS one. 2018 ; Vol. 13, No. 3.
@article{f2c28212bd8a45a5820e4c2562ef533f,
title = "Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan",
abstract = "Objective The study aimed to describe the evolution of the seroprevalence of hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-positive patients included in two cohorts in Taiwan. Methods We retrospectively collected the information on demographic and clinical characteristics of 4,025 and 3,856 HIV-positive Taiwanese, who were aged 18 years or older at designated hospitals around Taiwan in 2004±2007, when an outbreak of HIV infection was occurring, and 2012±2016, when the outbreak was controlled with the implementation of harm reduction program, respectively. Comparisons of HCV seropositivity were made among different age and risk groups for HIV transmission between these two cohorts. Results The overall HCV seroprevalence of the 2004±2007 cohort and 2012±2016 cohort was 43.4{\%} (1,288/2,974) and 18.6{\%} (707/3,793), respectively (P<0.001). The HCV seroprevalence among injecting drug users (IDUs), though decreasing, was constantly high across the two cohorts, 96.4{\%} and 94.0{\%} (P = 0.02), respectively, and all age groups. In contrast, the corresponding figures among men who have sex with men (MSM) and heterosexuals in the two cohorts were 5.9{\%} vs. 3.5{\%} (P = 0.002) and 9.4{\%} vs. 10.9{\%} (P = 0.59), respectively. Among sexually transmitted HIV-positive patients, HCV seropositivity was significantly correlated with age (adjusted odds ratio [aOR], per 1-year increase, 1.03; 95{\%} confidence interval [CI], 1.02±1.05) and a rapid plasma reagin (RPR) titer ≥1:8 (aOR, 1.58; 95{\%} CI, 1.03±2.43) in a multivariate analysis including age, gender, route for HIV transmission, baseline CD4 count and plasma HIV RNA load, the presence of hepatitis B surface antigen, and an RPR titer ≥1:8. Compared with heterosexuals, the aOR for HCV seropositivity among MSM was 0.47 (95{\%} CI, 0.31±0.72). Conclusions HCV seroprevalence among HIV-positive patients in Taiwan decreased with time, probably related to the inclusion of younger adults and more non-IDUs, and remained high among IDUs. HCV seropositivity was associated with age and an RPR titer ≥1:8 among patients who acquired HIV through sexual contact.",
author = "Chia-Wen Li and Yang, {Chia Jui} and Sun, {Hsin Yun} and Tsai, {Mao Song} and Lin, {Shih Ping} and Lin, {Te Yu} and Cheng, {Chien Yu} and Lee, {Yi Chien} and Huang, {Yu Shan} and Liu, {Chun Eng} and Lee, {Yuan Ti} and Tang, {Hung Jen} and Wang, {Ning Chi} and Cheng, {Shu Hsing} and Wen-Chien Ko and Hung, {Chien Ching}",
year = "2018",
month = "3",
day = "1",
doi = "10.1371/journal.pone.0194149",
language = "English",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

Li, C-W, Yang, CJ, Sun, HY, Tsai, MS, Lin, SP, Lin, TY, Cheng, CY, Lee, YC, Huang, YS, Liu, CE, Lee, YT, Tang, HJ, Wang, NC, Cheng, SH, Ko, W-C & Hung, CC 2018, 'Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan', PloS one, vol. 13, no. 3, e0194149. https://doi.org/10.1371/journal.pone.0194149

Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan. / Li, Chia-Wen; Yang, Chia Jui; Sun, Hsin Yun; Tsai, Mao Song; Lin, Shih Ping; Lin, Te Yu; Cheng, Chien Yu; Lee, Yi Chien; Huang, Yu Shan; Liu, Chun Eng; Lee, Yuan Ti; Tang, Hung Jen; Wang, Ning Chi; Cheng, Shu Hsing; Ko, Wen-Chien; Hung, Chien Ching.

In: PloS one, Vol. 13, No. 3, e0194149, 01.03.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan

AU - Li, Chia-Wen

AU - Yang, Chia Jui

AU - Sun, Hsin Yun

AU - Tsai, Mao Song

AU - Lin, Shih Ping

AU - Lin, Te Yu

AU - Cheng, Chien Yu

AU - Lee, Yi Chien

AU - Huang, Yu Shan

AU - Liu, Chun Eng

AU - Lee, Yuan Ti

AU - Tang, Hung Jen

AU - Wang, Ning Chi

AU - Cheng, Shu Hsing

AU - Ko, Wen-Chien

AU - Hung, Chien Ching

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective The study aimed to describe the evolution of the seroprevalence of hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-positive patients included in two cohorts in Taiwan. Methods We retrospectively collected the information on demographic and clinical characteristics of 4,025 and 3,856 HIV-positive Taiwanese, who were aged 18 years or older at designated hospitals around Taiwan in 2004±2007, when an outbreak of HIV infection was occurring, and 2012±2016, when the outbreak was controlled with the implementation of harm reduction program, respectively. Comparisons of HCV seropositivity were made among different age and risk groups for HIV transmission between these two cohorts. Results The overall HCV seroprevalence of the 2004±2007 cohort and 2012±2016 cohort was 43.4% (1,288/2,974) and 18.6% (707/3,793), respectively (P<0.001). The HCV seroprevalence among injecting drug users (IDUs), though decreasing, was constantly high across the two cohorts, 96.4% and 94.0% (P = 0.02), respectively, and all age groups. In contrast, the corresponding figures among men who have sex with men (MSM) and heterosexuals in the two cohorts were 5.9% vs. 3.5% (P = 0.002) and 9.4% vs. 10.9% (P = 0.59), respectively. Among sexually transmitted HIV-positive patients, HCV seropositivity was significantly correlated with age (adjusted odds ratio [aOR], per 1-year increase, 1.03; 95% confidence interval [CI], 1.02±1.05) and a rapid plasma reagin (RPR) titer ≥1:8 (aOR, 1.58; 95% CI, 1.03±2.43) in a multivariate analysis including age, gender, route for HIV transmission, baseline CD4 count and plasma HIV RNA load, the presence of hepatitis B surface antigen, and an RPR titer ≥1:8. Compared with heterosexuals, the aOR for HCV seropositivity among MSM was 0.47 (95% CI, 0.31±0.72). Conclusions HCV seroprevalence among HIV-positive patients in Taiwan decreased with time, probably related to the inclusion of younger adults and more non-IDUs, and remained high among IDUs. HCV seropositivity was associated with age and an RPR titer ≥1:8 among patients who acquired HIV through sexual contact.

AB - Objective The study aimed to describe the evolution of the seroprevalence of hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-positive patients included in two cohorts in Taiwan. Methods We retrospectively collected the information on demographic and clinical characteristics of 4,025 and 3,856 HIV-positive Taiwanese, who were aged 18 years or older at designated hospitals around Taiwan in 2004±2007, when an outbreak of HIV infection was occurring, and 2012±2016, when the outbreak was controlled with the implementation of harm reduction program, respectively. Comparisons of HCV seropositivity were made among different age and risk groups for HIV transmission between these two cohorts. Results The overall HCV seroprevalence of the 2004±2007 cohort and 2012±2016 cohort was 43.4% (1,288/2,974) and 18.6% (707/3,793), respectively (P<0.001). The HCV seroprevalence among injecting drug users (IDUs), though decreasing, was constantly high across the two cohorts, 96.4% and 94.0% (P = 0.02), respectively, and all age groups. In contrast, the corresponding figures among men who have sex with men (MSM) and heterosexuals in the two cohorts were 5.9% vs. 3.5% (P = 0.002) and 9.4% vs. 10.9% (P = 0.59), respectively. Among sexually transmitted HIV-positive patients, HCV seropositivity was significantly correlated with age (adjusted odds ratio [aOR], per 1-year increase, 1.03; 95% confidence interval [CI], 1.02±1.05) and a rapid plasma reagin (RPR) titer ≥1:8 (aOR, 1.58; 95% CI, 1.03±2.43) in a multivariate analysis including age, gender, route for HIV transmission, baseline CD4 count and plasma HIV RNA load, the presence of hepatitis B surface antigen, and an RPR titer ≥1:8. Compared with heterosexuals, the aOR for HCV seropositivity among MSM was 0.47 (95% CI, 0.31±0.72). Conclusions HCV seroprevalence among HIV-positive patients in Taiwan decreased with time, probably related to the inclusion of younger adults and more non-IDUs, and remained high among IDUs. HCV seropositivity was associated with age and an RPR titer ≥1:8 among patients who acquired HIV through sexual contact.

UR - http://www.scopus.com/inward/record.url?scp=85044174520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044174520&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0194149

DO - 10.1371/journal.pone.0194149

M3 - Article

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e0194149

ER -